Physician profile
Christopher N DO
NPI 1407876659
$3,806.25
in general payments reported to CMS, 2019-2025
20 companies · $1,274 in 2025
The $1,274 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $55.90 · 2021: $484 · 2022: $354 · 2023: $547 · 2024: $789 · 2025: $1,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,610.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,072.87 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $655.94 | 2024-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $372.84 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $243.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.86 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $179.54 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $150.00 | 2025 | |
| Abbvie INC. | $138.64 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $136.55 | 2023 | |
| Silk Road Medical, INC. | $126.80 | 2021 | |
| Inspire Medical Systems, INC. | $99.22 | 2023 | Inspire |
| Novartis Pharmaceuticals Corporation | $94.08 | 2023-2025 | |
| Lilly USA, LLC | $86.05 | 2024-2025 | Mounjaro, Jardiance |
| Ge Healthcare | $59.63 | 2024 | |
| Abbott Laboratories | $52.09 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $40.78 | 2023-2024 | Elyxyb |
| Aimmune Therapeutics, INC. | $34.62 | 2025 | Zenpep |
| Array Biopharma INC | $33.77 | 2025 | Braftovi, Tukysa, Mektovi |
| Incyte Corporation | $22.47 | 2024 | Jakafi |
| Pfizer INC. | $21.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.